Credits: IMDb
“I'm not great at the advice. Can I interest you in a sarcastic comment?”

This is what ‘Friends’ actor Matthew Perry’s character Chandler Bing was known for. He was known for being funny. However, he had his own struggles in his personal life and those struggles were acute depression. He was treating it with ketamine infusion therapy which is legal in the US and the UK.
Ketamine is an anaesthetic used to treat depression, anxiety and pain under supervised and controlled medical settings. However, it does have its side effects, which can lead to distortion of sight, sound and time. It can also produce calming and relaxing effects.
Ketamine increases a person’s heart rate and blood pressure. If overdosed, it can leave users confused and agitated and can cause them to hurt themselves without even realising it. It can also lead to liver damage and bladder problems.
However, when used in moderation and under the supervision of medical doctors, it can treat depression where traditional antidepressants have failed.
Prof Rupert McShane, a University of Oxford psychiatrist who runs an NHS ketamine treatment clinic told BBC that ketamine “probably turns off the area of the brain that is involved in disappointment.”
In simple terms, it cannot, be if the dosage is given in a controlled setting and as prescribed. Ketamine infusion therapy uses drugs in small doses than those used for anaesthesia. It acts faster than traditional anti-depressants, but the effects also wear off way quickly. Which is why it is important to monitor patients’ mental state for relapsing back into depression and discouraging them from overdosing on it.
There are ways of giving people ketamine. One of the ways is through “infusing”, which means to use an IV drip. However, injections, nasal sprays and capsules are also methods used to give people ketamine.
Since the dosage of ketamine used in the infusion treatment is small, it being the reason of actor Perry’s death was ruled out. The medical examiner also noted that Perry’s last ketamine infusion therapy session happened more than a week before his death, which means by the time he had died, it must have worn off.
Though Perry’s last session was more than a week before, his post-mortem showed that his blood contained a high concentration of ketamine. He had died of the “acute effects” of ketamine.
If it was not his session, then how did he get ketamine?
Prosecutors alleged that his assistant gave him at least 27 shots of ketamine in four days before his death, reported BBC.
Perry has been open about his personal struggles and this is what the doctors and dealers used against him. Martin Estrada, the US attorney for California’s Central District told the BBC that people took advantage of his condition. They charged him 165 times more than what vials of ketamine cost.
Names that have come up include Dr Salvador Plasencia, drug dealers “Ketamine Queen” aka Jasveen Sangha and Eric Fleming, and Perry’s live-in assistant Kenneth Iwamasa.
Ketamine Queen or Sangha supplied drugs that led to Perry’s death. Her home was a “drug-selling emporium,” said Estrada. More than 80 vials of ketamine, and thousands of pills including methamphetamine, cocaine and Xanax were allegedly found in her house known as the “Sangha Stash House.”
Sangha is known to deal with high-end celebs and was a “major source of supply for ketamine to others as well as Perry,” said Estrada.
Dr Plasencia called Perry a “moron” while charging him $2,000 for vials that cost only $12. He sold Perry 20 vials of ketamine between September and October 2023, costing $55,000.
He was the one who taught Iwamasa, who had no medical knowledge to inject the drug. This is after he knew that “Perry’s ketamine addiction was spiralling out of control,” as per what the investigators told the BBC.
Another dealer Fleming was told by Sangha to “delete all our messages.” While Fleming pleaded guilty to conspiring to distribute drugs unlawfully, he also allegedly messaged Sangha: “Please call...Got more info and want to bounce ideas off you. I’m 90% sure everyone is protected. I never dealt with [Perry] only his assistant. So the assistant was the enabler.”
The court documents also revealed that he asked Sangha on whether the ketamine stays in your system or “is it immediately flushed out.”
The people who allegedly exploited Perry used coded language for ketamine and called it “Dr Pepper”, “bots”, or “cans.”
Selling overpriced drugs, taking advantage of Perry’s mental condition and falsifying medical records to make the drugs given to him look legitimate by Dr Plasencia is what took Perry’s life.
Iwamasa is said to have administered more than 20 shots of ketamine and three on the day Perry died. Whereas ketamine is only administered by a physician. Authorities also found that weeks before Perry’s death, Dr Plasencia allegedly bought 10 vials of ketamine and intended to sell to Perry.
He also injected Perry with a large dose, two days later. This caused him to “freeze up” and spiked his blood pressure.
Perry had always been open about his drug addictions, struggles with alcohol and his depression. He said that his openness would help others who are also struggling and wanted to be remembered by his quote which also is on the homepage of the Mattew Perry Foundation that helps others struggling with the disease of addiction: “When I die, I want helping others to be the first thing that’s mentioned.”
Five arrests have been made in the case so far.
Credit: AI
Artificial intelligence has steadily been becoming a bigger part of the healthcare sector. One of the biggest examples is ChatGPT.
Open AI recently begun rolling out Health in ChatGPT to eligible users in the United States, allowing people to securely connect medical records, Apple Health data, and other supported health sources directly to ChatGPT.
The feature aims to help users in understanding their lab reports better, document their medical history, prepare for doctor visits, and gauge complex medical information.
While it promises convenience and personalised health insights, it has also sparked concerns about privacy, data security, and how much trust people should place in AI for healthcare decisions.
It is currently available on the web and iOS for eligible Free, Go, Plus, and Pro users in the US, with the rollout happening gradually.
Once connected, users can ask questions such as:
Instead of uploading reports every time, ChatGPT can use connected health information, with the user’s permission, to provide more personalized explanations.
Also read: AIIMS Doctor Issues Warning After Patient Follows ChatGPT Advice, Suffers Internal Bleeding
According to the company, “Health is designed to support; not replace, medical care and is not intended for final diagnosis or treatment. For urgent symptoms or emergencies, seek immediate professional help.”
The company also states, “Conversations in Health are not used to train our foundation models.”
Users can disconnect connected accounts whenever they choose. OpenAI says synced data from disconnected sources is deleted from its systems within 30 days, although information already included in conversation history remains unless users delete those chats.
Medical records often contain technical terminology that patients struggle to interpret.
AI can translate complicated reports into simpler language that laymen can understand.
Patients can review previous reports, organise symptoms, and prepare questions before appointments, making doctor visits more productive.
People often have information spread across hospital portals, physical files, wearable devices, and fitness apps.
ChatGPT can combine these sources to identify patterns over time, like changes in sleep, physical activity, or important bio markers.
Rather than searching through multiple reports manually, users can quickly compare test results or check long-term changes with simple prompts.
Also read: Man Falls Ill After Seeking ChatGPT Advice on Cutting Salt
Despite the advantages, experts caution against relying too heavily on AI for healthcare.
Although OpenAI has introduced additional security measures, users are still sharing extremely sensitive personal health information with an AI platform.
Some AI privacy experts argue that any cloud-based storage of medical information is risky.
ChatGPT can explain information but may misunderstand context, overlook rare conditions, or generate inaccurate answers.
OpenAI clearly states that the feature must not replace professional medical advice, diagnosis, or treatment.
The launch comes amid renewed scrutiny over AI-generated medical advice.
A recently filed lawsuit alleges that a user delayed seeking emergency treatment after relying on ChatGPT’s health guidance.
While the allegations are still part of ongoing legal proceedings, the case has intensified discussions about the limitations of AI in healthcare.
If your goal is to better understand your lab reports, organise medical information, or prepare for doctor consultations, ChatGPT Health could become a useful health assistant.
However, if you are expecting AI to diagnose illnesses, decide treatments, or replace healthcare professionals, experts say that would be a mistake.
Healthcare decisions often depend on physical examinations, medical history, imaging, and clinical judgment, areas where AI cannot replace qualified doctors.
Credit: AI
The human brain may begin undergoing important immune changes much earlier than previously thought. A recent study found that these changes could help explain why the risk of dementia increases with age.
Researchers found that the hippocampus, the brain region responsible for learning and memory, experiences a major shift in its immune cells during the 40s and 50s.
The findings suggest that this change could lead to chronic inflammation associated with Alzheimer's disease and other forms of dementia in the future .
The study, conducted by scientists from the University of California San Diego, the New York Genome Center, and the University of California Irvine, analysed postmortem hippocampal tissue from 40 neurologically healthy adults aged between 20 and 95 years.
Researchers examined more than 1.2 million brain cells, discovering that around midlife, the brain's immune environment changes dramatically.
One of the biggest findings involved microglia, the brain's resident immune cells. While these cells normally protect the brain by clearing debris, fighting infections, and supporting neurons, researchers observed that they gradually shift into a more inflammatory state during middle age.
This altered immune environment resembles patterns commonly seen in neurodegenerative diseases like dementia.
Scientists have long known that aging is the strongest risk factor for dementia. However, exactly how normal aging causes diseases like Alzheimer's has remained vague.
The new findings suggest that the process may begin decades before symptoms like memory loss appear.
Instead of viewing aging as a slow, continuous process, the study indicates that the brain may pass through a distinct biological transition during midlife.
Once this immune environment changes, it may make the brain more vulnerable to inflammation and cognitive decline.
Richard J. Hodes, MD, Director of the National Institute on Aging (NIA), said, "Aging is the single largest risk factor for dementia, but our understanding of how it drives disease is still incomplete. This previously hidden microglial shift, now uncovered by innovations in technology and thinking, may be an important clue to help us complete the puzzle."
The researchers also believe these immune changes may not simply be a consequence of aging but could actively influence how the brain ages.
Also read: Can One Partner's Dementia Raise the Other's Risk? New Study Suggests An Interesting Link
Although the findings do not mean that everyone in their 40s or 50s will develop dementia, they provide researchers with a potential window for clinical intervention.
If scientists can identify or modify these immune changes before significant brain damage occurs, future therapies may be able to delay or even prevent neurodegenerative diseases.
Experts continue to recommend:
These lifestyle measures are already known to reduce several risk factors associated with dementia, and the new findings suggest they may be particularly important during the brain's midlife transition.
Credit: AI
A six-year-old girl in China died after receiving an experimental gene-editing treatment for a rare neurodevelopmental disorder. The incident sparked scrutiny on ethics and safety of cutting-edge gene therapies, particularly when they involve children and individualized treatments.
The case, uncovered through a joint investigation by Science and Retraction Watch, sparked international concern as the child's death was never disclosed publicly, despite related preclinical research later being published in Nature.
According to the investigation, the six-year-old girl, identified by the pseudonym "Mei," had Snijders Blok-Campeau syndrome, a rare genetic condition. It caused symptoms like mild intellectual disability and developmental delays.
Her parents reportedly paid more than $800,000 to support development of a personalized ("n=1") gene-editing therapy designed specifically for their daughter's mutation.
In March 2025, she received a spinal infusion containing trillions of adeno-associated viruses (AAVs) carrying a CRISPR-based gene editor intended to correct the faulty gene in brain cells. Within days, she developed a severe immune reaction and died approximately one week after treatment.
An internal hospital review concluded that the most likely cause of death was an overwhelming immune response triggered by the viral delivery system rather than the gene-editing mechanism itself.
The controversy extends well beyond the patient's death. According to Science investigation:
Following the investigation, local Chinese health authorities reportedly fined the hospital involved for faulty execution of the clinical research. Several experts have called for an independent review of the published research and greater transparency around experimental human gene-editing trials.
Bioethicists and gene therapy researchers say the case underscores the need for complete transparency whenever experimental therapies are tested on humans.
Hank Greely, director of the Center for Law and the Biosciences at Stanford University, told Science that the trial "shouldn't have gone to trial".
Pediatrician Marcelo Bellusci, who participates in gene therapy trials, told El País, "In this type of trial there can be serious side effects, but families are always informed about them. This team skipped the current rules."
Gene-editing technologies such as CRISPR offer the possibility of correcting genetic mutations caused by diseases instead of simply treating symptoms. Several CRISPR-based therapies have shown remarkable success in inherited blood disorders, including sickle cell disease.
However, experts stress that therapies targeting the brain remain considerably more complex because they often require large viral doses and carry greater risks of immune complications.
As more individualized gene-editing therapies move toward human testing, experts argue that every serious adverse event must be reported promptly to regulators, journals, clinicians, and patients to ensure future treatments become both safer and more trustworthy.
© 2024 Bennett, Coleman & Company Limited